ArticleActa pharmaceutica Sinica. B2023
Rapidly separating dissolving microneedles with sustained-release colchicine and stabilized uricase for simplified long-term gout management.
Article in Acta pharmaceutica Sinica. B, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 56 citations in OpenAlex.
- Photoinitiator-free gelatin hydrogel microneedles for acute gouty arthritis treatment.Science advances · 2026Article
- Hyaluronic acid microneedle patch for transdermal delivery of naringin-loaded PEGylated terpesomes in a rat model of rheumatoid arthritis: Modulation TGF-β1, oxidative stress, and inflammation.International journal of pharmaceutics: X · 2026Article
- An AI-assisted designed supramolecularly engineered nanoplatform reverses pigmentation by triggering an ineffective compensatory melanin production program.Bioactive materials · 2026Article
- High-strength silk fibroin microneedles for transdermal colchicine delivery: a dose-response analysis demonstrating superior efficacy over oral administration.Drug delivery and translational research · 2026Article
- Biomaterial-Based Strategies for Gout Therapy: Recent Advances, Current Challenges, and Future Perspectives - A Review.International journal of nanomedicine · 2026Review
- Targeted suppression of CCR7/NF-κB signaling by apoptotic body-inspired colchicine nanovesicles halts atherosclerotic progression.Journal of nanobiotechnology · 2025Article
- Engineering microneedles for biosensing and drug delivery.Bioactive materials · 2025Review
- Microalgae-based hydrogel drug delivery system for treatment of gouty arthritis with alleviated colchicine side effects.Bioactive materials · 2025Article
- From mechanism to applications: Advanced microneedles for clinical medicine.Bioactive materials · 2025Review
- Development and Evaluation of Huperzine A-Loaded Microneedles for Transdermal Delivery and Pretreatment of GD Poisoning.AAPS PharmSciTech · 2025Article
- Progressive microneedles for targeting and intelligent drug delivery.Asian journal of pharmaceutical sciences · 2025Review
- Advances in microneedle-based drug delivery system for metabolic diseases: structural considerations, design strategies, and future perspectives.Journal of nanobiotechnology · 2025Review
- Engineered Microneedle System Enables the Smart Regulation of Nanodynamic Sterilization and Tissue Regeneration for Wound Management.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Advances in the use of nanotechnology for treating gout.Nanomedicine (London, England) · 2025Review
- Chitosan-Based Intelligent Microneedles for Delivery of Amphotericin B Loaded Oleosomes: Antifungal Ocular Patch Targeting for Effective Against Fungal Keratitis Using Rabbit Model via TLR4/NLRP3 Pathway.International journal of nanomedicine · 2025Article
- A Bibliometric Analysis of Microneedle-Mediated Drug Delivery: Trends, Hotspots, and Future Directions.Drug design, development and therapy · 2025Review
- Advances in drug delivery systems for the management of gout and hyperuricemia.Frontiers in pharmacology · 2025Review
- Advances in materials science for ocular diseases induced by cardiovascular risk factors.Frontiers in bioengineering and biotechnology · 2025Review
- Focused ion beam (FIB) prepared microtextured microneedle array capable of delivering drugs through punctured skin.Scientific reports · 2024Article
- Microneedles as an Emerging Platform for Transdermal Delivery of Phytochemicals.Molecular pharmaceutics · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite growing prevalence and incidence, the management of gout remains suboptimal. The intermittent nature of the gout makes the long-term urate-lowering therapy (ULT) particularly important for gout management. However, patients are reluctant to take medication day after day to manage incurable occasional gout flares, and suffer from possible long-term toxicity. Therefore, a safe and easy-to-operate drug delivery system with simple preparation for the long-term management of gout is very necessary. Here, a chitosan-containing sustained-release microneedle system co-loaded with colchicine and uricase liposomes were fabricated to achieve this goal. This microneedle system was confirmed to successfully deliver the drug to the skin and maintain a one-week drug retention. Furthermore, its powerful therapeutic potency to manage gout was investigated in both acute gouty and chronic gouty models. Besides, the drug co-delivery system could help avoid long-term daily oral colchicine, a drug with a narrow therapeutic index. This system also avoids mass injection of uricase by improving its stability, enhancing the clinical application value of uricase. In general, this two-drug system reduces the dosage of uricase and colchicine and improves the patient's compliance, which has a strong clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.